AstraZeneca dividend 2024: Pharma giant announces Rs 24/share dividend alongwith Q4 results
The drugmaker has also announced its financial results for the fourth quarter ended on March 31, 2024, along with a dividend announcement.
)
07:42 PM IST
The board of railway pharma giant AstraZeneca Pharma India has approved a final dividend of Rs 24 per equity share, according to a stock market disclosure.
"Recommended Dividend of Rs. 24/- per equity share for the financial year 2023-24," the company said in a BSE filing today, May 27.
The drugmaker has also announced its financial results for the fourth quarter ended on March 31, 2024, along with a dividend announcement.
AstraZeneca Pharma Q4FY24 earnings highlights
- Revenue from operations for financial year 2023-24 stood at Rs 1,296 crore with substantial 29 per cent increase.
- Earnings per share (EPS) for financial year stood at Rs 64.6 demonstrating a significant growth of 63 per cent.
"FY 2023-24 was one of the strongest years for us in the country and we take immense pride in our consistent performance. AstraZeneca India products sales for first time cross Rs 1000 crore mark, delivering total revenue of almost Rs ~1300 crore with growth of 29 per cent this year. A successful execution of our growth through innovation strategy is helping us propel our ambition to be pioneers in science and lead in specialist disease areas in India. Science is guiding us, and our remarkable pipeline progress with 9 new medicines and indication approvals that we received last year, positions us optimally and we feel motivated to bring more innovative therapies faster and closer to patients in India," said Sanjeev Panchal, Country President and Managing Director, AstraZeneca India.
Meanwhile, shares of AstraZeneca Pharma closed at Rs 6,441.05 each, up 7.14 per cent on BSE today.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
)
)
)
)
)
)
)
)
)
)
)
)
AstraZeneca Covid vax linked to another rare fatal blood clotting disorder
AstraZeneca vaccine booster works against Omicron, Oxford lab study finds
USFDA study shows Evusheld retains neutralising activity against Omicron: AstraZeneca
U.S. will accept mixed doses of vaccines from international travelers
